ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1206

Randomized Controlled Trial of Tacrolimus vs. Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease

Session Information

Category: Glomerular Diseases


  • Griffith, Megan, Imperial College NHS Trust, London, United Kingdom
  • Medjeral-Thomas, Nicholas R., Imperial College London, London, United Kingdom

Group or Team Name

  • MInTac Study Investigators

Standard treatment of de novo nephrotic syndrome secondary to Minimal Change Disease with high dose corticosteroids is associated with the risk of adverse side effects. However there is a paucity of Clinical Trials to guide the use of steroid free alternative regimens in this rare disease in adults. This multicentre prospective, open-label, randomised controlled trial (EudraCT 2009-014292-52, NCT00982072) involving 6 nephrology units across the UK investigated whether tacrolimus monotherapy without corticosteroids would be effective for the treatment of de novo minimal change disease. We hypothesised nephrotic syndrome remission rates would be non-inferior for tacrolimus monotherapy compared to corticosteroids


Adult patients with first presentation of minimal change disease and nephrotic syndrome were randomised to oral tacrolimus at 0.05mg/kg twice daily, or prednisolone at 1mg/kg daily up to 60mg daily. 50 patients completed the trial


There were no significant differences between the tacrolimus and prednisolone treated cohorts in the proportion of patients in complete remission at 8 weeks (primary outcome; 21 of 25 (84%) for prednisolone and 17 of 25 (68%) for tacrolimus (p=0.32)), at 16 weeks (23 of 25 (92%) for prednisolone and 19 of 25 (76%) for tacrolimus (p=0.25)), or at 26 weeks (23 of 25 (92%) for prednisolone and 22 of 25 (88%) for tacrolimus (p>0.99)). Likewise there was no difference in total remission rates (complete or partial) at 4 weeks (20 of 25 patients (80%) in the prednisolone and 19 of 25 patients (76%) in the tacrolimus cohort (p>0.99), or at the subsequent time points. There was no significant difference in relapse rates (17 of 23 (74%) for prednisolone and 16 of 22 (70%) for tacrolimus (p>0.99)), in the time from complete remission to relapse, or in changes from baseline serum creatinine.


Tacrolimus monotherapy treatment for adults with newly presenting minimal change disease was non-inferior to oral prednisolone in achieving remission from nephrotic syndrome. This is the 1st multicentre randomised controlled trial demonstrating an effective alternative for patients wishing to avoid steroid therapy. This heralds a new era in the management of adults with minimal change disease.